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Smokeless tobacco (SLT) use presents a very complex public health challenge globally, with nearly 356 million people using SLT in a variety of forms.1 Of these 356 million users, nearly 82% are in the South-East Asia Region (SEAR).1However, the burden is not limited to SEAR; in fact, 29 Parties to the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) report10% or more prevalence of SLT use among males or females or both. An increasing number of countries are encountering the problem, especially amongst the youth.2,3 It is scientifically established that SLT products can be highly addictive similar to cigarettes and other combustible tobacco products, many contain more than 30 carcinogens in high concentrations, and thier use in the oral cavity can lead to adverse health outcomes including cancer (oral, pharyngeal, oesophageal and pancreatic).4 SLT is also associated with a 2 to 4 times increase in the risk for cardiovascular deaths and still-births.5 The diverse varieties of SLT products manufactured, marketed and used in different parts of the world present further challenges in effective global recommendations for the regulation of these products. In several countries, SLT is used along with other products, especially alkalizing agents like slaked lime to increase the release of alkaloids and areca nut, which is itself, a Group-I carcinogen.6
The WHO FCTC remains the primary international tool for tobacco control and applies equally to all tobacco products, including SLT products. However, several Parties to the Treaty consider SLT use as a regional concern limited to SEAR and some commentators and health experts have portrayed SLT as a less harmful alternative to smoking.7–10 Although the all-cause mortality attributable to SLT products may be lower than cigarettes, it is still significant accounting for over 650,000 deaths annually.10a There is a wide variety of SLT products that are used across the world.  Not every SLT product carries the same health risks. The popularity of different products differs in different geographic regions. The overall burden of SLT products, therefore, varies from country to country e.g. SLT specific disease burden is much higher in South East Asia than in the United States.11 The difference is particularly stark between high income and other countries.1 The myriad ways of SLT use make effective global recommendations for regulation of SLT products a difficult task. This is challenged further by lack of data, research and evidence base - slowing down policy progress on SLT prevention and control. Limited information and updates on SLT indicators are available from the WHO FCTC Convention Secretariat’s Global Progress Report on implementation of the Treaty, WHO Report on the Global Tobacco Epidemic and the WHO FCTC Global Knowledge Hub on Smokeless Tobacco. Moreover, information from several countries on SLT is inadequate or not available. 





An assessment of comparable indicators for cigarettes and SLT products was undertaken to gauge the global progress in SLT control policies while identifying the gaps, opportunities and challenges in the implementation of various provisions of the WHO FCTC. 

Search strategy and selection criteria

Inclusion Criteria: Published data were drawn from different sources such as the Global WHO FCTC Implementation Progress Reports 2012,12 2014,132016,14and 201815WHO reports on the global tobacco epidemic 2013,16 201517 and 2017,18 WHO-NCI Monograph,19 Global Tobacco Surveillance System Data20 which includes different rounds of the Global Adult Tobacco Survey, the Global Youth Tobacco Survey, the Global Health Professions Student  (​https:​/​​/​www.cdc.gov​/​tobacco​/​global​/​gtss​/​gtssdata​/​​)Survey and the Global School Personnel Survey. In addition, other official data sources at the country, regional and global levels, including SLT control reports, survey reports, monographs,4,21 tobacco control legislation and regulations,22that were available in the English were reviewed. A descriptive analysis is presented to examine the prevalence, trends and policy progress in advancing SLT control across Parties. The paper focuses on evaluating the implementation and impact of SLT control measures in 180 Parties to the Treaty 

Exclusion criteria: The ‘European Community’ (it represents a group of countries from the European Union that are already included in 180 Parties), countries that are not a Party to the WHO FCTC and data not available in English, were excluded.

The analysis, in describing the evidence for specific SLT interventions and policies is not limited by country, however, in describing progress on implementing SLT interventions it is limited to the 180 countries that are Party to FCTC.







The indicators used for the analysis of the status of SLT policy implementation corresponding to different Articles of WHO FCTC and the number of Parties with available data on these indicators are summarized in Table 1. In what follows, we present the findings specific to each article.

The global attention on prevention and control of SLT came with the implementation of the WHO FCTC and the decision of the Conference of Parties (COP) to request the WHO, ‘for a comprehensive report based on the experience of the Parties on SLT prevention and control’.23 Documents and reports on SLT were considered by COP at its 4th24, 5th25 and 6th26 sessions. All these reports highlighted the existence of myriad varieties and diverse characteristics of SLT products globally and the inherent challenges in their regulations – SLT products are largely produced in traditional and informal markets. One of the key recommendations from these reports, for the Parties, was to apply tobacco control policy interventions for cigarettes and other smoking forms of tobacco to SLT products as well.26 It was also recommended that comprehensive implementation of the WHO FCTC for regulating all tobacco products, including SLT products, was vital to the regulation of SLT products.26

A total of 138 Parties define SLT under their domestic tobacco control law (Table-1 below and Table-1 of Supplement-I). The global policy implementation of the WHO FCTC measures for SLT prevention and control has remained limited and varied, even in the countries with high SLT burden. This analysis highlights the wide gap in the implementation of SLT control policies when compared to smoking control policies globally.

Table-1: Number of Parties having data on WHO FCTC article wise SLT indicators

Price and tax measures (Article 6)

There are 138 Parties that have defined SLT products to some extent within their domestic tobacco control legislation. However, only 34 Parties have reported some data on SLT price and/or taxes and only 11 Parties have two-point in time data (Table-1) (Table-1 of Supplement-II).17,18 In almost half of these countries, the price of a 20 gm SLT product is less than a dollar, in comparison to the global average price of a 20-cigarette pack of $4.87 (adjusted for purchasing power). The price of SLT products (20 gm pack) is lower than the average price of cigarettes (20-cigarette pack) even in low-income-countries (LIC) at $3.03 and lower middle-income countries (LMIC) at $4.31. The underlying assumption of the comparison of SLT product and cigarette is that one cigarette stick contains approximately 1 gm of tobacco. Although, a gram of SLT and a stick of cigarette may not be strictly equivalent in terms of nicotine intake, the price difference in obtaining a standard pack of each product shows the significant difference in affordability between the two alternative tobacco products.  

The relatively low price of SLT products compared to cigarettes is attributable to the fact that the tax rates applied to SLT products are generally lower than the tax rates for cigarettes.19 While the WHO Technical Manual on Tobacco Tax Administration recommends tobacco excise taxes should account for at least 70% of the retail prices of tobacco products,30 only four Parties had a total tax incidence (including excise and other taxes) at or above 70% of retail prices. In other words, taxation as a tool to regulate SLT use is highly underutilized among most Parties, even where feasible. 

Low levels of SLT tax and prices with moderate increases contribute to growing affordability of SLT products and undermine the effectiveness of tax and price policies in reducing SLT consumption. Studies from India and Bangladesh (two largest SLT burden Parties) show that SLT products are becoming more affordable in India and have maintained the same level of affordability in Bangladesh in the recent past despite tax and price increases.31,32 Evidence from these countries suggests that the tax and price increases for SLT products have not been adequate to counteract the effects of inflation and income growth.33 

Unlike the evaluation of the effectiveness of tax and price increases in reducing cigarette demand, the documentation of the effectiveness of SLT taxation and pricing appears to be far less than adequate. Only a handful of studies have assessed the price sensitivity of demand for tobacco products other than cigarettes. Studies from India27 and Bangladesh28 show that increasing the price of SLT products reduces SLT consumption significantly. These studies also show that the demand for SLT is price inelastic, i.e. increase in prices of such product, through taxation, for example, would result in reducing consumption to a proportion less than the increase in price while increasing revenue from SLT taxation. A meta-analysis of the available estimates of price elasticity of demand for non-cigarette products that a 10% increase in SLT price will result in a 2.1% reduction in SLT consumption confirming the price inelasticity of SLT demand.29 These findings align with the evidence available for cigarette tax and price policies.

The evidence on the substitutability of SLT and combustible tobacco products is even more limited. Only one study from Bangladesh shows positive cross-price elasticity of demand for SLT products and cigarettes, suggesting that increases in the price of cigarettes without concomitant increases in the price of SLT products can induce switching from cigarette smoking to SLT use and increase SLT consumption.28 In other words, tax and price policy cannot be effective in reducing overall tobacco consumption when it is designed and implemented for one tobacco product in isolation from potentially substitutable other tobacco products.  
In the face of the limited evidence based on price sensitivity and affordability of SLT products, there is a need to undertake research in other high SLT burden countries to generate comprehensive and robust global and regional estimates of price elasticity and affordability of SLT products. There is also no evidence on the unintended consequences of tax and price increases (e.g., tax avoidance and evasion) and the measures to address these concerns. Such efforts will augment effective use of price and tax measures under the WHO FCTC and help in reducing the consumption of SLT products, while generating more tax revenues.

Regulation of content and emissions and their disclosures (Article 9 & 10)

Implementation of Article 9 and 10 of the Convention has also remained wanting, as several Parties have not been able to undertake any kind of testing of the chemicals in tobacco products. Even the tests that are conducted pertain mainly to cigarettes, with only six Parties carrying out the test of SLT products (Table-1). With regard to SLT product regulation, the WHO Study Group on Tobacco Products Regulation recommended comprehensive regulatory control by an independent, scientific government agency to take steps to reduce the appeal of and addiction to SLT products (e.g., eliminate flavours, control pH), need for regulation of the levels of toxicants in SLT products (e.g.,set upper limit for tobacco-specific nitrosamines NNN plus NNK, benzo[a]pyrene, monitor levels of arsenic, cadmium and lead etc.) and regulate adding non-tobacco ingredients into SLT products (e.g., areca nut).34,35,35a The Conference of Parties of the WHO FCTC, at its seventh session called for finalising the standard operating procedures for measuring nicotine, tobacco-specific nitrosamines and advice on the applicability of the WHO Tobacco Laboratory Network (TobLabNet) standard operating procedures to measure humectants and ammonia in SLT and need to identify any available technical approaches to reduce toxicants in SLT.36

Regulation of chemical composition of SLT products has been carried out only by 13% (n=6) of the Parties, and even there, not all kinds of available SLT products have been analysed (Table-2 of Supplement-III).37 With respect to SLT product regulation, 31 Parties prohibit any quantitative display of contents whereas, 21 Parties have mandated display of qualitative information on the constituents and emissions of SLT products on its packaging (Table-1).

Packaging and labelling of tobacco products (Article 11)

Tobacco product packaging and labelling have been considered effective tobacco control measures and were amongst of the provisions of FCTC to be implemented within three years of coming into force of the Treaty. Albeit slow, the progress in implementing effective and stronger health warnings on tobacco products in the majority of the Parties has focused on cigarettes. Global research on pack warning is also largely based on cigarettes and negligible on other tobacco products including SLT38, though evidence sufficiently establishes that effectiveness of health warnings applies to them as well.39,40

Nine Parties have adopted plain packaging of tobacco products and 16 others are considering the same,41 however, the inconsistency in the implementation of the health warnings on SLT products versus cigarettes is rampant  across Parties. This is evident from the fact that only 14 Parties mandate pictorial health warnings larger than 50%of the pack size on SLT products (Table-1), while 67 Parties require the same for cigarettes.41,42 Pictorial health warnings are also implemented by a fewer number of Parties on SLT (23% (n=41) of the Parties) while 66% Parties implement the same on cigarettes (Table-1 of Supplement-IV). 

Awareness, education and communication (Article 12)

One of the core guiding principles of the Treaty under Article 4.1 prescribes that “every person should be informed of the health consequences, addictive nature and mortal threat posed by tobacco consumption and exposure to tobacco smoke.” Although more than two-thirds of the Parties report the implementation of Article 12 and use its guidelines for creating awareness, much of the efforts focus on cigarettes or against exposure to tobacco smoke. While, nearly two-thirds of the Parties conducted a national mass media campaign against tobacco smoking only 36% (n=65) of the Parties defining SLT have implemented the same for SLT (Table-1).18 However, only a couple of Parties, dedicated national mass media to SLT control and even lesser had it evaluated.43 Although, one of the most cost-effective means of awareness, education and communication is pictorial health warnings, only 14 Parties have greater than 50% PHWs on SLT products (Table-1). 18

The Global Tobacco Surveillance System (GTSS) captures data through four surveys across key tobacco control measures. These surveys have been conducted in over 150 countries. However, it fails to capture key data on anti-SLT information, education and awareness with several Parties not including the SLT optional questions during their national surveys (Table-1). So far, this information is only available for India and Bangladesh (Supplement-V). There is a lack of effort to disseminate awareness, education and communication on SLT. Several studies from high SLT burden Parties in the South-east Asia Region points to this need, including measures specifically targeted to vulnerable populations.44–50 However, both electronic and print media have been widely used in the region for disseminating information on the health hazards of tobacco use in general. This earned media coverage of various tobacco control events, initiatives, research and evidence on tobacco use, including SLT, has helped in mass communication of the ill effects of tobacco use.

Advertisement, promotion and sponsorship (Article 13)

A comprehensive ban on tobacco advertisement, promotion and sponsorship (TAPS) helps in reducing tobacco use, especially among the youth and other vulnerable sections of the population. Anything less than a comprehensive ban provides an opportunity for the tobacco industry to aggressively market their products. TAPS ban is one of the time-bound obligations for the Parties requiring them to undertake the measures necessary to implement the ban within five years of ratification.

Though Parties have implemented bans on various kinds of TAPS, both on SLT and cigarettes, exposure to the advertisement, promotion and sponsorship of SLT products remains higher in comparison to cigarettes.21 Analysis of the country reports on the implementation of the Treaty suggests that nearly 9% (n=16) of the Parties have a comprehensive ban on TAPS of SLT products (Table-1 of Supplement-VI).  Advertisements at the point of sale (banned only in 43% of the Parties), in international print and electronic media, as well as, cross-border advertisements including internet sale and promotion remains the biggest global challenge.51 Only 26% (n=47) Parties have complete ban on sponsorship (Table-1).  Evidence suggests that exposure to SLT advertisements among youth in high SLT burden Parties, like India is still very high. According to Global Youth Tobacco Survey conducted in India, about 70% students saw advertisements for SLT products on ‘Billboards’, while 50% reported ‘appearance of SLT on television and/or films’.21 Furthermore, there is suggestive evidence that SLT advertising is more likely to influence consumption in women than men.52 

Treatment from SLT dependence and cessation (Article 14)

According to the WHO Report on the Global Tobacco Epidemic 2017, only one-third of the world population has opportunities to access an effective tobacco cessation programme. There is also considerable variation in access to behavioural support offered by health professionals, with SLT users having relatively poor access than smokers, especially in countries like India53, Bangladesh, Kenya, Pakistan, Thailand and Uganda.54 The percentage of smokers who were advised to quit by a health care provider was higher than that of SLT users in these countries.54

Although nicotine replacement therapy (NRT), as an option for tobacco cessation, is available in more than 50% of the Parties, access to NRT is limited due to several factors including cost.55 Only 21% (n=38) Parties include it in essential medicines list (Table-1). Evidence shows that standard pharmacotherapy used for smokers is not equally successful in SLT users.4Comprehensive NRT and cessation support is available only in three Parties (Table-1 of the Supplement VII). There is limited evidence that NRTs are effective in enhancing long-term treatment success, but have been shown to reduce withdrawal symptoms and craving during SLT abstinence. On the other hand, in one study, Varenicline has been shown to demonstrate efficacy with snus users, but its, side-effects, availability and cost has remained a concern.4
With the use of technology in providing tobacco cessation support, 24 Parties now provide mCessation support. A study of more than 12,000 registered users of mCessation facilities in India, demonstrated an average quit rate of about 7% among smokers and SLT users after 6 months of enrolment.18 Globally, unlike smoking cessation, there is a lack of access to intervention for SLT cessation,56 as well as, inadequate training among the majority of health professionals and school teachers.57 Available E-learning modules on tobacco cessation for health professionals are also lacking on skill training on SLT.
Protection of minors from exposure to SLT (Article 16)

The Framework Convention envisions protecting the health of present and future generations from the ill effects of tobacco use, by banning the sale to minors. In 2005, when FCTC came into force, the number of Parties that had prohibited sale of tobacco products to minors was 31, but by 2016 this increased to 141. Minors have generally been defined as persons below the age of 18 years but in some cases cutoff age of 16 years, 20 years and 21 years are also used.

The Convention Article 16 recommends Parties, in their policy to protect minors, to include the following key provisions: (a) Placing warning boards at the point of sale; (​http:​/​​/​grammar.ccc.commnet.edu​/​grammar​/​marks​/​semicolon.htm​) (b) Prohibition of tobacco product display in such a manner that it is directly accessible; (c) Ban on tobacco products in the form of sweets, toys, candies, etc.; and, (d) Prohibition of vending machines. However, only 13% Parties have implemented these four key provisions under their domestic laws (Table-1 of the Supplement-VIII). Direct access to tobacco products at the point of sale (74%) and sale of loose cigarette/SLT products (90%) remains the key concern areas (Table-1). The sale of loose tobacco products also interferes with the tobacco product packaging and labelling regulations.

Research, Surveillance and Exchange of Information on SLT (Article 20)

There is clear-cut evidence of SLT use among adults’ in 137 countries (Table-1); however, there is insufficient data to measure changes over time at the global level as recent data on SLT use is available only for a limited number of Parties for both adults (n=55%) and adolescents (n=70) (Table-1). With several Parties collecting comparable data on tobacco use in different cycles, only a handful of Parties (n=16) were identified as having comparable datasets across all reporting cycles for adult SLT use.  Thus, there is rather limited availability of comparable data from Parties on prevalence and pattern of SLT use.58 Ninety percent of SLT use burden is in LIC or LMIC group of countries,1 while 29 Parties have SLT use prevalence of 10% or more among male or female or both (Table-5 of the supplement-IX).

With more than 80% of the SLT users in South-East Asia, a clear shift in the product preference from smoking to SLT has been noted in the region. SLT use among adult men has been increasing in Bangladesh, India and Nepal.59 Data from the Myanmar WHO STEPWise Survey, indicates highest prevalence of SLT use among men (62.2%), while among women also prevalence is substantial (24.1%).60 













Price and tax measures

FCTC Article 6 Guidelines recommend measures to progressively increase taxes on all tobacco products including SLT. Any tax increase introduced for cigarettes and other smoked tobacco products should also be applied to SLT products to avoid substitution. Tax and price increases for SLT products should be indexed to inflation and income growth to arrest the growing affordability of SLT products. Parties should also consider measures to strengthen tax administration and prevent tax evasion, provided under Article 6 Guidelines.

Regulation of content and emissions and their disclosures

There is a need for developing or upgrading the capacity to test and measure the contents of SLT products in all regions. Efforts should be intensified to develop and verify/validate SOPs for testing key contents of SLT and agree on methods that could be utilised globally. Parties, especially in South-east Asia could make use of the tobacco testing laboratories recently established in India. Future work to review practices to address toxicity, addictiveness and attractiveness of SLT products should be intensified, this could also inform the further development of the Articles 9 and 10 Guidelines. Encouraging, international collaboration among research groups to undertake such research and coordination between their efforts is highly desirable, especially in view of wide diversity of SLT products.

Packaging and labeling of tobacco products

Article 11 of the Convention requires Parties to implement large, pictorial warnings on tobacco products. Appropriate warnings should be developed for SLT products:  messages relevant to SLT products are needed where such products are available in the market; regulations should prescribe minimal dimensions that make the health warnings visible and effective; mandate health warnings (both graphic and text) also at points of sale. An inventory of SLT-specific health warnings should be created and added to the WHO FCTC Health Warnings Database.63The proportional size of pictorial warning should be the same as that specified for cigarettes.

Awareness, education and communication

An inventory of SLT-targeted media campaigns, educational programmes and other culturally relevant interventions should be produced and disseminated broadly.  SLT-specific campaigns should be created, including on social and mass media. These may include health spots in movies and TV programmes; locally relevant communication programmes, as well as tailor-made education and communication programmes  to bring about change in norms, believes and behaviour. An additional objective of SLT specific educational material would be to dispel myths surrounding so called ‘benefits’ of SLT use in the population. There is further need to evaluate such interventions for their effectiveness as outlined in the Article 12 Guidelines.

Advertising, promotion and sponsorship

Comprehensive measures required under FCTC Article 13 and its Guidelines should be put in place to ban all forms of TAPS. Additionally, the resources on best practices available from the Parties should be shared and utilised. Cross-border advertising needs to be addressed in any national legislation, regulation and policy, as well as international cooperation should be strengthened (e.g., through the Expert Group on cross-border advertising established at COP7 on this matter).64

Treatment of SLT dependence and promoting cessation 

There is a need to broaden the scope of any brief advice, mHealth initiative and quitlines to include and promote SLT cessation in line with FCTC Article 14 Guidelines. Countries’ health systems should be more responsive in addressing SLT use; to this end, there is a need for sensitising and training health care professionals, including dentists, to inquire about SLT use and provide advice on how to quit. Additionally, efforts should be made to integrate SLT cessation into relevant health programs and services, including but not limited to TB and HIV/AIDS control, oral health, reproductive health, substance abuse and NCDs. Research groups in high prevalence countries should conduct further research to assess the effectiveness of SLT cessation interventions. 

Protection of minors from exposure to SLT 

The sales of SLT products to and by minors and their sale in small single use packs/sachets should be prohibited. Such provisions required under FCTC Article 16 should be included in any national tobacco control legislation, regulation and policy as well as other relevant legislation, including those on child and juvenile protection. High and deterrent penalties should be imposed for selling SLT to minors.

Research, Surveillance and Exchange of Information on SLT





Given that SLT use is a global problem, particularly in South-east Asia, and based on the above findings and discussions on the global SLT policy scenario, it may be concluded that Parties to the Treaty require a comprehensive approach in implementing the provisions of the Convention to address the challenges identified for SLT control. Following key recommendations may be taken up on priority to inform the work of the Parties, non-Parties and other global, regional, national and sub-national stakeholders to prevent and control SLT use globally:

1.	Include all forms of tobacco products explicitly under the legal definition for comprehensive regulation of traditional and novel smoking and SLT products.
2.	Consider taxing all kinds of tobacco products without any exemptions, at a rate uniform with other comparable products and adjusted to inflation and income growth.
3.	Develop, verify and validate SOPs for testing key contents of SLT products and present comprehensive guidelines for Articles 9 and 10 with special reference to SLT for adoption by COP9.
4.	Specify multiple messages relevant to SLT products and prescribe minimal dimensions of such packs and standardization of packs that make the health warnings on SLT products visible.
5.	Develop and implement locally relevant, tailor-made comprehensive educational campaigns to dispel myths related to SLT use among specific target populations to bring behavior change. 
6.	Implement comprehensive TAPS ban for SLT, including cross-border TAPS.
7.	Train and build the capacity of the health professionals to provide behavioural interventions specifically for SLT cessation.
8.	Prevent sale of SLT products to and by minors while implementing the comprehensive provisions under Article 16.
9.	Monitor SLT use patterns and trends as well as its impact on health, economic, social and environmental aspects for implementing comprehensive SLT control policies globally.
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